Home > Insider Trading > Filing (0001209191-21-042752)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1850119	Century Therapeutics Inc.	IPSC	Pharmaceutical Preparations (2834)	1231

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1144145	Aktiengesellschaft Bayer	Kaiser-Wilhelm-Allee 1 Leverkusen 2M 51373		No	No	Yes	No
1820027	B.v. Investments World Bayer	Energieweg 1 Mijdrecht P7 3641RT		No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2021-06-22	10,390,600	$0.00	10,390,600	No	4	C	Direct
Common Stock	Acquisiton	2021-06-22	1,535,238	$0.00	11,925,838	No	4	C	Direct
Common Stock	Acquisiton	2021-06-22	750,000	$20.00	12,675,838	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series B Preferred Stock	Disposition	2021-06-22	26,143,790	$0.00	10,390,600	$0.00
Common Stock	Series C Preferred Stock	Disposition	2021-06-22	3,862,813	$0.00	1,535,238	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Direct
0			No	4	C	Direct

Footnotes

Shares of Series B Preferred Stock converted into shares of Common Stock at the closing of the Issuer's initial public offering at a 2.5161-for-1 conversion ratio for no consideration, and had no expiration date.
The securities reported are held directly by Bayer World Investments B.V., a Dutch private limited company, which is an indirect, wholly owned subsidiary of Bayer Aktiengesellschaft, a German stock corporation. Accordingly, Bayer Aktiengesellschaft may be deemed to be an indirect beneficial owner of the shares beneficially owned directly by Bayer World Investments B.V.
Shares of Series C Preferred Stock converted into shares of Common Stock at the closing of the Issuer's initial public offering at a 2.5161-for-1 conversion ratio for no consideration, and had no expiration date.